Skip to main content


Figure 2 | Orphanet Journal of Rare Diseases

Figure 2

From: Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome)

Figure 2

Percent change in 6MWT distance in Korean male patients with attenuated type Mucopolysaccharidosis II. At 24 weeks, the percent changes in 6MWT distance were significantly higher in idursulfase beta groups treated at dosages of 0.5 mg/kg/week (* P = 0.003) and 1.0 mg/kg/week († P = 0.015), compared to comparator group. White bars represent the comparator group (N = 8), grey bars represent the idursulfase beta 0.5mg/kg/week group (N = 6), and black bars represent the idursulfase beta 1.0mg/kg/week group (N = 7).

Back to article page